Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: SAN.PAR
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Sanofi (SAN) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

STRONG BUY

€83

+11.8%+15.1% incl. dividends

2031

5-Year

BUY

€102

+38.1%+60.0% incl. dividends

Published batch insight

Immunology Cash Engine Offsets Approaching Exclusivity Cliff Amid Strategic Pipeline Renewal

High consensus indicates robust near-term operating cash flows driven by expanding immunology indications and specialty launches will sustain generous capital returns. However, sharp divergence persists regarding terminal valuation durability, as the looming 2031 compound patent boundary and recent clinical pipeline attrition cap sustained multiple expansion.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Warren Buffett (Value Purist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), Superintelligence (Anthropologist), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Sanofi at the forecast anchor (2026-09-18): $16,650 in five years versus $13,892 for S&P 500 benchmark.

Sanofi · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 3.0% net dividend yield for Sanofi.

Figure: Five-year synthesized consensus value path for Sanofi compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in EUR; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 74.05 EUR1-year price return: +11.77%5-year price return: +38.06%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in EUR, with returns and rationale
Quarter	Target (EUR)	Quarter return	Total return	Forecast rationale
Q4 2026	76.45	+3.24%	+3.24%	Third-quarter results confirm robust respiratory volume expansion and launch portfolio scaling, reassuring investors following summer pipeline impairments. Systematic share buybacks absorb residual selling pressure, supporting modest multiple stabilization into year-end trading.
Q1 2027	78.96	+3.28%	+6.63%	Full-year earnings validate double-digit operating growth, meeting upgraded guidance. Capital allocation clarity following the consumer carve-out and sustained dividend declarations provide fundamental downside protection, encouraging institutional accumulation from oversold valuation levels.
Q2 2027	80.51	+1.97%	+8.73%	Annual dividend detachment creates typical seasonal price drag, partially cushioned by solid first-quarter operational cash flows. Specialty launch adoption across European markets continues broadening, though macro rate pressures keep multiple expansion measured.
Q3 2027	82.77	+2.80%	+11.77%	Accelerating prescription momentum across expanded respiratory indications confirms commercial operating leverage. Portfolio pruning and manufacturing transfers progress smoothly, allowing clean operating profit expansion to offset mature brand pricing concessions in regulated markets.
Q4 2027	85.37	+3.14%	+15.28%	Strong autumn infant RSV immunization shipments and seasonal vaccine deliveries boost fourth-quarter revenue. Ongoing float reduction from disciplined buybacks amplifies per-share earnings growth, driving steady capital appreciation into the annual close.
Q1 2028	88.24	+3.37%	+19.17%	Fiscal results show core business operating margins widening toward twenty-eight percent as commercial scale absorbs research overhead. The board announces another progressive dividend increase, reinforcing cash generation durability despite lingering exclusivity debates.
Q2 2028	89.72	+1.68%	+21.17%	Dividend distributions temporarily temper equity momentum, though underlying specialty care cash flows remain resilient. Rare disease therapies gain market share across North America, softening headline reimbursement headwinds from statutory healthcare price containment.
Q3 2028	91.65	+2.15%	+23.77%	Commercial execution across non-flagship launches demonstrates genuine franchise diversification. Contribution margins improve as initial launch costs moderate, allowing steady business earnings growth to support equity value even as pipeline replacement assets remain discounted.
Q4 2028	93.65	+2.18%	+26.47%	Peak respiratory immunization revenues provide strong seasonal cash conversion. Investors gain clearer visibility into late-stage neuroimmunology trial timelines, maintaining constructive sentiment and supporting modest multiple expansion before medium-term patent discussions intensify.
Q1 2029	96.14	+2.66%	+29.84%	Annual disclosures confirm record free cash flow generation exceeding nine billion euros. Management emphasizes balance-sheet preservation over speculative megadeals, anchoring investor trust and delivering steady per-share accretion through ongoing share count reduction.
Q2 2029	97.59	+1.51%	+31.80%	Annual dividend detachment and intensifying US payer rebate pressures create transient valuation friction. However, international specialty sales growth and stable gross margins above seventy percent protect underlying earnings, holding share prices steady.
Q3 2029	99.25	+1.70%	+34.04%	Specialty therapies achieve mature commercial efficiency, allowing operating income to grow faster than top-line revenue. Prudent bolt-on licensing reinforces the development pipeline without stressing conservative leverage, driving modest defensive outperformance.
Q4 2029	101.14	+1.90%	+36.58%	Solid third-quarter volumes across rare blood disorders and immunology sustain full-year guidance delivery. Strong operational execution offsets emerging biosimilar litigation headlines, closing the fiscal year with resilient free cash conversion.
Q1 2030	102.70	+1.54%	+38.69%	Full-year results highlight peak flagship revenue delivery, but market attention shifts decisively toward the approaching March 2031 patent deadline. Sell-side models begin publishing post-exclusivity earnings bridges, neutralizing operational outperformance.
Q2 2030	103.17	+0.46%	+39.32%	Substantial dividend yields and solid quarterly cash conversion anchor equity pricing during the annual distribution window. Investors demand tangible evidence of secondary formulation patent durability, keeping forward valuation multiples tightly rangebound.
Q3 2030	103.59	+0.41%	+39.90%	Pre-expiry operating cash generation remains robust, supported by established launch cohorts and operational spending discipline. However, terminal value discounting accelerates as biosimilar competitors reveal regulatory preparation, capping further valuation progress.
Q4 2030	103.19	-0.39%	+39.35%	Approaching patent expirations trigger tactical institutional de-risking ahead of the final exclusivity year. Reverse operating leverage concerns on fixed commercial infrastructure induce valuation multiple contraction, outweighing resilient underlying quarterly cash flows.
Q1 2031	101.39	-1.74%	+36.93%	Primary United States compound patent expiration arrives, generating sharp headline volatility and litigation focus. Cautious analyst revisions and initial pricing uncertainty prompt controlled valuation compression, cushioned only by high dividend yields.
Q2 2031	101.10	-0.29%	+36.53%	Post-expiration commercial disclosures show initial volume erosion remains manageable due to complex biologic manufacturing barriers and patient inertia. Generous dividend payments attract contrarian value buyers, stabilizing trading at discounted levels.
Q3 2031	102.23	+1.12%	+38.06%	Diversified revenue streams from established rare disease, neurology, and vaccine franchises cushion initial legacy exclusivity losses. Equity pricing achieves a durable terminal equilibrium, supported by solid cash conversion and disciplined capital stewardship.

The investment thesis rests on an asymmetric temporal mismatch: intermediate biological earning power is underpriced, yet terminal durability remains legitimately constrained. Expanding respiratory indications for the primary immunology asset and accelerating adoption of newer rare disease and pediatric immunization therapies drive high-single-digit sales growth and expanding operating margins. Strong cash conversion and divestment liquidity comfortably support disciplined share repurchases and progressive dividends. Valuation sensitivity centers on whether secondary delivery patents and pipeline assets can extend cash-flow duration beyond the March 2031 compound patent boundary, or whether reverse operating leverage will erode terminal multiples.

Key insights

Divestment liquidity and high free cash conversion insulate near-term capital returns, providing structural downside protection even if broader macroeconomic discount rates stay elevated.
Pruning uncompetitive Phase 3 assets protects near-term operating margins and return on invested capital, yet increases reliance on targeted external business development.
Severe terminal valuation discounts already reflected in single-digit earnings multiples reduce downside asymmetry, making execution in launch diversification the primary alpha driver.

Deep Dive

Market consensus treats the company as a vulnerable single-blockbuster enterprise destined for sharp terminal decay once core United States patent exclusivity expires in March 2031. Sell-side research anchors heavily on historical clinical trial discontinuations, pricing the equity at a persistent single-digit multiple that discounts intermediate cash generation and treats non-flagship portfolio diversification as unproven.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value, creating meaningful underpricing. The market's central blind spot is treating terminal patent risk as an immediate impairment rather than an event five years away. By capitalizing a patent cliff prematurely, the crowd overlooks that expanding respiratory indications and new rare disease launches generate substantial recurring cash flows before exclusivity lapses. Furthermore, the market fails to credit the capital allocation optionality created by substantial consumer divestment proceeds, which fund accretive share repurchases.

Repricing catalyst

Consecutive quarterly earnings releases demonstrating sustained double-digit specialty care expansion and operating margin leverage will force consensus multiple normalization. The trigger will be visible commercial acceleration across newly launched hemophilia and infant respiratory therapies alongside continued volume compounding in chronic obstructive pulmonary disease. As share count reductions visibly enhance per-share business earnings through the 2027 reporting cycle, institutional allocators will be compelled to close the unwarranted peer valuation discount.

Published consensus context

Macro regime alignment

The macroeconomic backdrop of restrictive central-bank benchmark rates and elevated sovereign yields represents a net relative tailwind. While higher discount rates compress long-duration biotech multiples, the company's inelastic biological demand, robust gross margins, and minimal financial leverage insulate it from debt refinancing shocks, attracting defensive capital rotations seeking dependable cash yields.

Published consensus context

Advisor disagreement

The primary analytical disagreement across reports concerns terminal multiple behavior ahead of the March 2031 United States patent expiration. Constructive views argue that exceptional near-term cash generation, consumer divestment proceeds, and launch portfolio diversification will drive multiple rerating toward twelve to fifteen times earnings. Conversely, skeptical perspectives emphasize reverse operating leverage, asserting that a fixed commercial cost base facing biologic genericization justifies persistent single-digit multiples. Resolving this tension requires observing whether non-flagship launches sustain double-digit growth while secondary formulation patents survive initial judicial challenges.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Flagship respiratory indication volume compounding: The core immunology biologic continues compounding volume across chronic obstructive pulmonary disease and newly approved respiratory indications. Surpassing five billion euros quarterly, this high-margin franchise benefits from physician prescribing inertia and entrenched market access. The resulting operational leverage expands operating earnings and funds capital returns through late decade, despite eventual patent boundaries; assessed likelihood is 90%. Expected impact: +25%.
Specialty launch portfolio commercial scaling: Non-flagship pharmaceutical launches, spearheaded by therapies for hemophilia A, infant respiratory syncytial virus protection, and multiple myeloma, are expanding at roughly fifty percent annually. Generating over five billion euros with gross margins above eighty percent, this commercial scaling diversifies revenue streams away from single-asset reliance and steadily builds durable post-cliff earning power; assessed likelihood is 85%. Expected impact: +18%.
Divestment liquidity deployment into buybacks: Monetizing control of the consumer healthcare division crystallized approximately ten billion euros in net cash proceeds. Directing surplus liquidity into structured share repurchases at compressed valuation multiples permanently shrinks the share count. This capital return mechanism mechanically accelerates per-share earnings growth and establishes a resilient valuation floor against broader equity market fluctuations; assessed likelihood is 80%. Expected impact: +14%.
Operational discipline and portfolio pruning: Executive leadership has instituted rigorous capital allocation by discontinuing non-differentiated clinical programs and transferring mature manufacturing sites to strategic partners. Eliminating redundant clinical expenditures and shedding low-margin legacy facilities lowers fixed operating overhead. This restructuring expands core business operating margins toward thirty percent, increasing cash conversion efficiency on remaining commercial sales; assessed likelihood is 75%. Expected impact: +11%.

Top frictions and headwinds

Impending compound patent exclusivity cliff: The primary United States compound patent for the core immunology franchise expires in March 2031, with European boundaries approaching concurrently. Generating over a third of group sales, this revenue concentration causes institutional investors to discount terminal cash flows aggressively. This structural overhang persistently compresses price-to-earnings multiples, capping valuation expansion despite robust near-term volume delivery; assessed likelihood is 95%. Expected impact: -18%.
Late stage clinical research attrition: High-profile clinical discontinuations, exemplified by terminating amlitelimab in eczema alongside past regulatory setbacks in neurology, reveal ongoing internal pipeline renewal deficits. Writing off capitalized developmental expenditures forces management to sustain elevated research outlays near eighteen percent of revenue. This ongoing clinical attrition delays organic revenue replacement and reinforces investor skepticism; assessed likelihood is 90%. Expected impact: -13%.
Statutory drug pricing reimbursement containment: Implementation of United States Medicare drug price negotiations and tightening European statutory rebate frameworks steadily compress net realized pharmaceutical prices. As top-selling specialty therapies enter mandatory discount schedules, gross-to-net price realization erodes across key commercial lines. This regulatory drag dampens gross margin expansion and demands higher volume throughput to maintain baseline earnings growth; assessed likelihood is 85%. Expected impact: -10%.
Macroeconomic rates and currency translation: Persistent central-bank monetary tightening maintains elevated discount rates, reducing the net present value of long-dated biopharmaceutical cash flows. Furthermore, generating over forty percent of revenue in North America while reporting in euros exposes earnings to foreign exchange volatility and cross-border trade friction. These currency translation headwinds routinely shave points off reported revenue and business earnings; assessed likelihood is 80%. Expected impact: -8%.

Tail risks

Accelerated biosimilar patent estate invalidation: Adverse court rulings or successful inter partes reviews could invalidate secondary formulation and delivery patents before 2030, enabling aggressive biosimilar entry immediately upon March 2031 compound expiration or earlier. Triggered by coordinated litigation from generic consortia, rapid formulary displacement would collapse net realized pricing by over sixty percent within two years, permanently eroding group operating profits and endangering dividend expansion; probability is 30%. Probability: +30%. Expected impact: -30%.
Severe clinical toxicity or regulatory hold: Emergence of unanticipated drug-induced liver injury or severe systemic safety signals in late-stage neurology or immunology programs could force regulatory clinical holds by 2028. Triggered by safety surveillance or pivotal trial failures, immediate asset abandonment would generate multi-billion-euro intangible impairments, eliminate key post-cliff replacement pillars, and force panic-driven, dilutive M&A that impairs balance-sheet strength and shareholder returns; probability is 25%. Probability: +25%. Expected impact: -22%.

Tail opportunities

Frexalimab breakthrough in multiple sclerosis: Pivotal Phase 3 clinical trials for anti-CD40L antibody frexalimab could demonstrate definitive disease progression reduction in secondary progressive multiple sclerosis by 2028. Triggered by superior neuroprotective efficacy and clean hepatic safety, regulatory approval in this underserved population would unlock over three billion euros in peak commercial sales. This clinical validation would decisively resolve post-cliff revenue succession, expanding forward valuation multiples; probability is 35%. Probability: +35%. Expected impact: +25%.
Secondary patent defense extends exclusivity: Successful legal defense of high-concentration formulations, novel autoinjector devices, and extended four-weekly dosing schedules could legally push effective commercial exclusivity in the United States beyond 2033. Triggered by favorable federal court rulings against early biosimilar challenges by 2028, this outcome would protect billions in high-margin cash flows, restoring terminal value confidence and triggering aggressive multiple rerating toward global peer averages; probability is 30%. Probability: +30%. Expected impact: +28%.

What to monitor

Thesis watchpoints

-- Confirmation: Non-flagship specialty launch sales sustain annualized growth above 20% through late 2027, verifying commercial diversification away from single-asset reliance.

Key insights

Deterioration: Group core operating margin compresses below 25% or annual free cash flow drops below 8 billion euros across consecutive reporting quarters.
Reassessment: Federal court decisions or biosimilar filings emerge before 2029 that invalidate secondary formulation patents, pulling forward exclusivity expiration assumptions.

Company Financial Analysis

Sanofi Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Headline financial reports show sharp profit swings that conceal an underlying commercial acceleration. In fiscal 2025, revenue reached 46.7 billion euros with net income expanding to 7.81 billion euros. While second-quarter 2026 reported accounting profit dropped sharply to 343 million euros, this decline was driven by a one-off 1.03-billion-euro pipeline impairment following the termination of uncompetitive eczema studies, rather than falling medicine demand. Underneath these accounting charges, core business performance is strengthening. Driven by blockbuster immunology demand and rapid uptake of infant respiratory and hemophilia therapies, quarterly operating sales grew by double digits. Management consequently upgraded full-year 2026 constant-currency sales targets to approximately 10%.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	EUR 46.7B	EUR 7.8B	EUR 9B
2024	EUR 44.3B	EUR 5.6B	EUR 5.9B
2023	EUR 41.1B	EUR 5.4B	EUR 8.6B
2022	EUR 40.3B	EUR 8.4B	EUR 8.3B
2021	EUR 39.2B	EUR 6.2B	EUR 8.5B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	9.5x	TTM	Native	EUR / EUR
2024	20.5x	TTM	Native	EUR / EUR
2023	20.8x	TTM	Native	EUR / EUR
2022	13.5x	Annual	Native	EUR / EUR
2021	17.8x	Annual	Native	EUR / EUR

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Underlying profit margins reflect powerful commercial pricing power driven by high-value specialty biologics. Gross margins expanded to 72.1% in 2025, demonstrating that complex medicines command premium prices across global healthcare systems. While reported operating margins temporarily dipped to 20.5% due to clinical write-downs and restructuring costs, core business profitability remained strong. Selling off lower-margin consumer lines structurally lifts future profit margins toward 28% to 30%. As blockbuster respiratory indications scale and the launch portfolio expands without requiring proportional overhead, operating leverage will naturally widen profit margins, generating massive cash flows to reinvest in the business and reward shareholders.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	EUR 9.6B	20.5%	16.7%
2024	EUR 14.5B	32.6%	12.6%
2023	EUR 13B	31.6%	13.1%
2022	EUR 13.1B	32.6%	20.8%
2021	EUR 8.1B	20.7%	15.9%

Balance sheet and leverage

AI Review

The balance sheet stands as a financial fortress, offering immense security in a world of high interest rates. At the close of 2025, total equity stood at 71.4 billion euros against a conservative debt-to-equity ratio of 0.28, supported by strong interest coverage exceeding ten times earnings. The company faces virtually no borrowing distress. Strategic resilience expanded dramatically following the sale of a controlling stake in the consumer healthcare division, which delivered approximately 10 billion euros in net cash proceeds. This liquidity injection virtually eliminated net debt, giving leadership complete flexibility to fund multi-billion-euro share repurchases and selective biotech acquisitions without risking credit downgrades.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	EUR 20.3B	EUR 7.7B	EUR 12.9B net debt	1.09x
2024	EUR 17.9B	EUR 7.9B	EUR 10.5B net debt	1.46x
2023	EUR 18.4B	EUR 9B	EUR 9.7B net debt	1.27x
2022	EUR 21.5B	EUR 12.7B	EUR 8.5B net debt	1.42x
2021	EUR 22.5B	EUR 10.1B	EUR 12.3B net debt	1.44x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management is demonstrating disciplined capital stewardship by shifting investment away from physical brick-and-mortar factories toward clinical scientific innovation. Physical capital expenditures accounted for just 3.8% of revenue in 2025, freeing up substantial cash flow. Instead of constructing unnecessary manufacturing plants, the company directs its capital firepower into research and development, which totaled 7.84 billion euros in 2025. This spending pattern reveals strict return-on-capital discipline under new executive leadership. Deciding to swiftly halt ineffective drug trials preserves capital rather than throwing good money after bad. Reallocating research budgets into high-conviction neurology and immunology candidates protects profit margins and focuses investment on durable, high-return medicines.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	EUR 1.8B	EUR 7.8B
2024	EUR 3.2B	EUR 7.4B
2023	EUR 1.6B	EUR 6.5B
2022	EUR 2.2B	EUR 6.5B
2021	EUR 2B	EUR 5.7B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	STRONG_BUY	323	+16.1%	Not available	ORIGINAL
5Y	BUY	178	+65.4%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	76.27	76.54	77.01	14
+6M	March 18, 2027	77.03	79.11	80.86	14
+9M	June 18, 2027	78.48	81.31	83.29	14
+1Y	September 18, 2027	80.15	83.52	86.62	14
+15M	December 18, 2027	81.75	86.32	89.22	14
+18M	March 18, 2028	84.2	88.98	93.68	14
+21M	June 18, 2028	85.04	91.03	97.43	14
+2Y	September 18, 2028	86.74	92.92	100.35	14
+27M	December 18, 2028	85.01	95.35	104.36	14
+30M	March 18, 2029	87.56	97.47	108.54	14
+33M	June 18, 2029	89.31	99.29	111.79	14
+3Y	September 18, 2029	90.2	100.79	114.03	14
+39M	December 18, 2029	92.01	102.69	115.17	14
+42M	March 18, 2030	92.01	103.95	118.63	14
+45M	June 18, 2030	92.86	104.72	121	14
+4Y	September 18, 2030	91	105.31	121	14
+51M	December 18, 2030	88.34	105.82	122.21	14
+54M	March 18, 2031	85.69	104.64	124.65	14
+57M	June 18, 2031	83.89	104.8	122.16	14
+5Y	September 18, 2031	82.21	105.89	123.38	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

EURUSD.FOREX forecast context

The batch's original direct_listing_to_usd path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 1.15 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	1.127	1.136	1.1385
+6M	March 18, 2027	1.1045	1.1255	1.1385
+9M	June 18, 2027	1.0934	1.1272	1.1499
+1Y	September 18, 2027	1.0934	1.1312	1.1614
+15M	December 18, 2027	1.1044	1.1401	1.173
+18M	March 18, 2028	1.0824	1.1452	1.1847
+21M	June 18, 2028	1.0715	1.151	1.1966
+2Y	September 18, 2028	1.0823	1.1584	1.2085
+27M	December 18, 2028	1.0931	1.1617	1.2085
+30M	March 18, 2029	1.0822	1.1694	1.2206
+33M	June 18, 2029	1.0713	1.1719	1.2328
+3Y	September 18, 2029	1.0713	1.1763	1.2328
+39M	December 18, 2029	1.0713	1.1781	1.2452
+42M	March 18, 2030	1.082	1.1832	1.2452
+45M	June 18, 2030	1.0712	1.1867	1.2576
+4Y	September 18, 2030	1.0605	1.1894	1.2699
+51M	December 18, 2030	1.0605	1.1887	1.2826
+54M	March 18, 2031	1.0711	1.1913	1.2826
+57M	June 18, 2031	1.0818	1.1971	1.2826
+5Y	September 18, 2031	1.0818	1.1964	1.2955

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

Independent factual verification reveals a clear division across reports regarding pipeline reality. Multiple reports failed basic data freshness checks by treating amlitelimab in atopic dermatitis as an active late-stage asset, directly contradicting the confirmed July 24, 2026 regulatory withdrawal and accompanying 952-million-euro impairment. These obsolete submissions were heavily downweighted to prevent distorted terminal expectations. Conversely, reports grounded in primary regulatory filings, audited half-year results, and verified corporate disclosures receive dominant weighting. These establish that underlying operational momentum is strong: the flagship immunology franchise is accelerating through respiratory label expansions, specialty launches like hemophilia and RSV therapies are diversifying revenues, and the consumer health carve-out provides substantial liquidity for share retirements. The strongest credible contrarian insight recognizes that while near-term cash conversion is robust, the approaching March 2031 United States compound patent boundary imposes reverse operating leverage that strictly caps multiple expansion.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight16.0/100

This assessment earns high weighting by verifying continuing-operations accounting against SEC filings, recognizing the July 2026 amlitelimab termination, and distinguishing group revenue from shared Regeneron collaboration economics. Its modeling of compound patent expiration without assuming automatic cliff collapse provides an economically rigorous, highly grounded valuation anchor.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight16.0/100

Weighted highly for forensic precision. It accurately details the Q2 2026 pipeline impairment, dissects the difference between IFRS and business EPS, and incorporates the Section 232 tariff shelter and MFN pricing dynamics. Its disciplined view on patent cliff multiple compression reflects superior factual grounding.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight12.0/100

Awarded substantial weight for sound owner-earnings discipline. It integrates the July 2026 clinical discontinuations, accurately examines specialty launch momentum in Altuviiio and Beyfortus, and establishes realistic discounted cash-flow boundaries without assuming multiple rerating into an impending patent expiration boundary.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight10.0/100

Merits meaningful weight for rigorous balance-sheet scrutiny and accurate recognition of the July 2026 non-cash impairment. It correctly captures the commercial acceleration of Altuviiio and Beyfortus, although its medium-term price targets rely on multiple expansion that somewhat discounts looming biosimilar litigation timelines.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight9.0/100

Receives moderate weight for accurately acknowledging the amlitelimab discontinuation and tracing Opella transaction liquidity into buybacks and late-stage neuroimmunology. While its multiple expansion assumptions are somewhat generous given looming patent boundaries, its analysis of Beyfortus adoption and non-cyclical biological demand is causally robust.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight9.0/100

Supported by solid verification of the amlitelimab write-down and thorough examination of non-Dupixent launches. It provides a unique, well-grounded insight into Regeneron collaboration loan extinguishment, though its medium-term valuation multiples are slightly optimistic relative to historical pharmaceutical de-risking cycles.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight9.0/100

Earns solid weighting for an accurate synthesis of executive governance, R&D triage, and Opella transaction dynamics. It properly notes the amlitelimab impairment and examines French sovereign industrial alignment, providing credible causal mechanics behind share repurchases and operating margin stabilization.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight6.0/100

Granted moderate weight for correctly incorporating the amlitelimab termination charge while accurately capturing Dupixent's chronic obstructive pulmonary disease volume acceleration. However, its aggressive valuation rerating to seventeen times earnings overstates institutional appetite ahead of the 2031 loss-of-exclusivity window.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight6.0/100

Receives modest weighting. It correctly identifies the amlitelimab impairment and Altuviiio launch traction, while soundly evaluating how Opella liquidity buffers share count compression. However, its bull-case assumptions regarding frontier synthetic biology displacement and long-range multiple expansion lack near-term empirical grounding.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight2.0/100

Downweighted primarily due to factual pipeline obsolescence, treating amlitelimab Phase 3 data in eczema as an active catalyst while missing the July 2026 abandonment. However, its analysis of sovereign balance sheet health, Opella liquidity deployment, and late-cycle macroeconomic defensiveness offers modest contextual value.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight2.0/100

Downweighted due to internal contradictions and pipeline inaccuracies. The report treats amlitelimab as an ongoing Phase 3 pipeline asset in risk modeling, overlooking the July 2026 termination. While its cash conversion and dividend coverage frameworks are sound, the clinical premise error weakens its forward forecasts.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight1.0/100

Heavily downweighted due to stale clinical premises. The report projects Phase 3 approval and commercialization for amlitelimab in atopic dermatitis, completely ignoring Sanofi's official July 24, 2026 discontinuation and subsequent impairment charge. Unverified cash-flow yields and unadjusted multiples further diminish its analytical utility.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight1.0/100

Assigned minimal weight because it relies on outdated pipeline assumptions. It models amlitelimab Phase 3 clinical de-risking and FDA approval as primary growth drivers, directly contradicting the confirmed July 2026 program cancellation. This core factual error undermines its projected operating margin trajectory and earnings forecasts.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight1.0/100

Assigned minimal weight due to critical factual inconsistencies. Despite noting executive turnover, it heavily bases its bull scenario and timeseries trajectory on amlitelimab Phase 3 atopic dermatitis registration and launch, completely ignoring the program's verified July 2026 discontinuation and impairment.

Skip to references

Research Provenance

References & Context

This Sanofi consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 99 deduplicated sources retained for this batch.

01regn-20251231sec.gov
02Sanofi - Form 6-K - FY2026sec.gov
03sny-20251231sec.gov
04sny-20260630_d2sec.gov
05www.sec.govsec.gov
06SANOFI PRESS RELEASE Q2 2026 1 Press Releasesanofi.com
07Sanofi drug pipeline worries, Dupixent dependence shake shares | 95 KQDS95kqds.com
08Sanofi outlook and pipeline, shares steady as analysts track Dupixent growthad-hoc-news.de
09Sanofi stock holds steady as analysts see upside from asthma pipelinead-hoc-news.de
10Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
11RBC Capital initiates Sanofi stock at Sector Perform on transition risks By Investing.comca.investing.com
12U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
14With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivityfiercepharma.com
15JPM26: Sanofi demonstrates significant strategic progress with several novel drugsfinance.yahoo.com

And 84 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: EUR, USD (quote EUR; primary reporting EUR; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.